MIRA Pharmaceuticals, Inc.
MIRAHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, MIRA Pharmaceuticals, Inc. (MIRA) is listed under Drug Manufacturers - General. Valued at $38.5M, MIRA is a micro-cap name in its sector. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
Market Cap
$38.5M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-2.24
EPS (TTM)
$-1.27
EPS (Fwd)
$-0.41
ROE
-184.3%
ROA
-112.7%
Cash
$9.4M
Total Debt
$0
Free CF
-$428,220
52W Change
-47.6%
Annual Financials
Cash vs Debt
Where MIRA stands vs its 150-day and 200-day moving averages
As of the July 13, 2026 close, MIRA finished 20.51% below its 150-day moving average ($1.17) and 25.00% below its 200-day moving average ($1.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MIRA overbought or oversold?
At the July 13, 2026 close, MIRA's RSI(14) was 45.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MIRA Pharmaceuticals, Inc. reports $9.4M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$428K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -184.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MIRA.